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In modern medicine, almost any part of the body can be
replaced by an artificial implanted device. Due to a growing
number of people with degenerative diseases, and thanks to
the evolving technology of implants, the use of implanted
medical devices is steadily increasing. Since more than
50 years, biomaterials have been developed for the use in
human medicine. The first breakthrough in the research
field of artificial organs was the replacement of degenerated
joints in the 1960s. In the meantime, the knowledge about
biomaterials has immensely evolved. Of note, the term
‘biomaterial’ is not only used for biological substances, but
also for synthetic materials in implants.
Organs with complex function such as lung, liver,
pancreas, heart and kidney cannot be permanently replaced
by totally implanted artificial devices, but only by organ
transplantation [1]. If in patients with terminal heart failure
no organ is available, the failed heart can be replaced by a
left ventricular assist device. However, this is not a definite
solution, because not the whole device can be implanted in
the body. Part of the device (electrical leads and battery) is
still outside of the body [2]. Due to the connection between
the intracorporal and extracorporal part of the device,
infection and inadequate clotting remain as major problems.
Therefore, the total artificial heart cannot yet permanently
replace the damaged organ, but only bridge the time until a
donor organ is available [2].
In contrast to the mentioned organs, other parts of the
human body, such as joints, blood vessels or crucial
components of organs (e.g. heart valves) can be replaced
with implanted devices made from biomaterials of different
complexity. Whereas, transplantation is hampered by
shortage of organs, implantation of artificial devices
exclusively depends on technology, surgical skills and
financial means. Patients receiving organs commonly have
to be immunosuppressed in order to avoid rejection.
Implanted devices, however, are, in general, perfectly
accepted by the host, whether they are made of devitalized
organic material or of various synthetic materials [3]. The
main drawback of transplanted organs is apparently the
need for prolonged (stem cell transplantation) or even life-
long (solid organ transplantation) immunosuppression. The
disadvantages of implanted artificial devices are less
obvious. They can be summarized as increased susceptibil-
ity to perioperative exogenous infection, life-long risk for
haematogenous implant-associated infection, suboptimal
function leading to inflammation (e.g. wear particles),
inadequate clotting (e.g. vascular devices) or haemolysis
(e.g. mechanical valves especially in case of paravalvular
leakage). Part of these problems will be covered in this
special issue of Seminars in Immunopathology.
The most frequently used implants are in the field of
orthopaedic surgery, namely internal fixation devices after
bone fracture and artificial joints for primary osteoarthritis.
During a 15-year period, the number of primary hip
arthroplasty increased 1.6-fold to 226,811, and the one of
primary knee arthroplasty 2.8-fold to 459,594 in the USA
alone [4]. Therefore, the outcome after implantation of an
orthopaedic device is not only important for the individual
patient, but also has an economic impact.
This special issue of Seminars in Immunopathology
focuses on the interaction between the host, its immune
system and the artificial organ. It is indeed intriguing to
follow these interactions between own and foreign. In view
of the important role of orthopaedic implants, several
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orthopaedic aspects are presented in different contributions
in this issue of Seminars in Immunopathology.
The review by Anderson and McNally [5] clearly shows
that foreign devices are not inert, but that the host reacts
with a well-defined part of the immune system. The extent
of this host reaction can be graduated as biocompatibility.
Innate as well as adapted cell interactions occur at sites of
implanted devices. In addition, even systemic effects can be
observed with certain devices. The authors discuss the
example of a systemic effect of the left ventricular assist
device on host defence. In patients with a left assist device,
circulating CD4+ lymphocytes decrease by apoptosis.
Furthermore, B-lymphocyte activation interferes with later
donor heart acceptance. This illustrates that biocompatibil-
ity does not only relate to the behaviour of biomaterial at
the site of implantation, but to a systemic reaction within
the whole body also.
In the contribution of Binnebösel et al. [6], the reaction
of the organism to prosthetic mesh grafts in abdominal
surgery is presented. For mechanical reasons, meshes, of
chemically different materials, are mainly used to repair
hernias. The authors discuss the biocompatibility of specific
chemical and physical characteristics of mesh grafts.
In orthopaedic surgery, mechanical stability of bone is
crucial for an optimal functional result. Peter E. Ochsner [7]
describes in his review the mechanisms that relate to
osteointegration. Not only the type of material, but also
the area of implantation is crucial for the process of
osteointegration. In addition, shape, elasticity and surface
structure of the implant are important factors defining the
result regarding biocompatibility and biomechanics.
The friction of material after total joint replacement
results in different amounts of wear particles. The review
by Catelas et al. [8] highlights the effect of wear particles
on the host. Accumulation and phagocytosis of such
particles induce liberation of pro-inflammatory cytokines,
a process which may lead to device loosening at the site of
implantation. This biological response is dependent on
chemical and physical characteristics of the particle.
After implantation of a device, osteointegration is
beneficial for the host. However, heterotopic ossification
is a feared complication occurring after various orthopaedic
interventions. Zeckey et al. [9] show in their review that
only little is known about the host factors inducing
heterotopic ossification. They review pathophysiologic
factors, risk factors, prevention and treatment options.
Since almost three decades, there is a debate regarding
the association of silicone breast implants with connective
tissue diseases. After an initial observation in Japan, a
causal correlation between autoimmune disorders and
silicone breast implants has been repeatedly claimed. In
their contribution, Lipworth et al. [10] review the
literature in the field, and conclude that there is no causal
connection between silicone breast implants and connec-
tive tissue diseases.
Implantation of a foreign device in the host is not rarely
complicated by infection, not only exogenously at time of
surgery, but life-long by haematogenous seeding. Factors
leading to this increased susceptibility to implant-associated
infection are summarized in the review of Zimmerli and
Sendi [11]. The main problem is the locally acquired
inefficient host defence around foreign devices. Many of
the reviews in this issue show limitations and unwanted
effects of implanted devices. In the future, it is conceivable
that tissue engineering overcomes these drawbacks [12].
Weber et al. [13] present in their review that this technology
is no longer pure science fiction. Cardiovascular tissue
engineering has already been shown to work in animals.
This technology is promising and may replace the need of
artificial devices in the future, at least in some fields of
medicine.
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